Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ROIV
ROIVANT SCIENCES LTD.
NASDAQ
$34.41
▲ UP 0.67% (0.23)

KEY STATISTICS

Market Cap$24.65 B
52w High$37.97
52w Low$12.54
Dividend Yield—
Frequency—
P/E-32.74
Volume6.86M
Shares Out.722.41M

COMPANY

LEADERSHIP

Matthew Gline
CHIEF EXECUTIVE
Matthew Gline

COMPENSATION 2026

Salary$75,000
Stock Awards$2,261,908
Incentive Plan Pay$0
All Other Comp.$20,163,986
Total$24,400,210

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 8, 2020
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
721

PRICE TARGET

Target High$42.00
Target Low$36.00
Target Median$41.00
Target Consensus$40.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$3.92M
NOV
9
MON

PRICE

$34.41 ▲ UP 0.67% (+$0.23)
$33.80$34.00$34.20$34.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM34.41

About Roivant Sciences Ltd.

https://roivant.com ↗

Roivant Sciences Ltd. is a London-based biopharmaceutical and healthcare technology company founded in 2014 that develops medicines for various conditions, including cancers, autoimmune diseases, skin disorders, and infectious diseases.

INDUSTRY

Biotechnology

A PRODUCT ROIVANT SCIENCES LTD. IS KNOWN FOR

VTAMA (tapinarof) cream, 1%
VTAMA (tapinarof) cream, 1%

A commercial-stage, FDA-approved topical aryl hydrocarbon receptor agonist treating plaque psoriasis and atopic dermatitis, generating revenue and validating Roivant's 'Vant' drug development model.

COMPETITORS

COMPETITOR
AMGN COMPARE
ARQT COMPARE
INCY COMPARE
LLY COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ2-2025Q3-2025Q4-2025Q1-2026
Reportable Segment$1.57M $2M ▲$4.69M ▲$1.44M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
293
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.02% · 16.0M
XUU.TO
0.02% · 15.8M
XMMO
2.53% · 5.4M
XBI
1.10% · 3.7M
SCHM
0.29% · 1.2M
DFAC
0.08% · 1.2M
FCMO.TO
1.34% · 699.7K
AAUB
2.68% · 660.8K
TMSL
0.32% · 275.0K
ADPV
4.67% · 247.2K
JHMM
0.14% · 245.8K
FPX
0.54% · 233.3K
BBMC
0.36% · 225.0K
USVM
0.31% · 161.2K
LABU
0.73% · 124.4K
VETS
1.60% · 76.7K
AVUS
0.02% · 74.5K
PTL
0.27% · 69.3K
IQSM
0.59% · 59.7K
BBP
1.38% · 48.7K
GSGO
0.85% · 43.2K
BKLC
0.02% · 40.2K
RECS
0.02% · 39.3K
BIB
0.83% · 25.7K
SAMM
2.37% · 22.4K
WDNA.L
1.51% · 18.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.66%
HOLDERS
586
TOP 12 OF 586 · RANKED BY POSITION SIZE
Fmr LLC
81.0M sh · $2.87B
Morgan Stanley
58.4M sh · $1.27B
Blackrock, Inc.
48.2M sh · $1.71B
Vanguard Group Inc
42.1M sh · $912.68M
Sb Investment Advisers (Uk) Ltd
40.3M sh · $609.97M
Blackrock Inc.
35.4M sh · $373.86M
Qvt Financial LP
29.4M sh · $444.54M
Viking Global Investors LP
23.6M sh · $356.99M
Ubs Group AG
22.6M sh · $626.56M
Rubric Capital Management LP
20.0M sh · $302.6M
State Street Corp
18.7M sh · $282.93M
Goldman Sachs Group Inc
18.6M sh · $656.71M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Lisa McClain
Lisa McClain
Purchase
2025-06-17

INSIDER TRADES

★
OFFICER: PRESIDENT & IMMUNOVANT CEO
Venker Eric
Sale · 200.0K shares
2026-08-28
★
OFFICER: PRESIDENT & IMMUNOVANT CEO
Venker Eric
Purchase · 200.0K shares
2026-08-28
★
OFFICER: PRESIDENT & IMMUNOVANT CEO
Venker Eric
Sale · 166.2K shares
2026-08-28
★
OFFICER: PRESIDENT & IMMUNOVANT CEO
Venker Eric
Sale · 33.8K shares
2026-08-28

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OVERWEIGHT 2
OUTPERFORM 1
NEUTRAL 1
10 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Citigroup BUY Guggenheim BUY TD Cowen BUY Piper Sandler OVERWEIGHT Leerink Partners OUTPERFORM Goldman Sachs BUY Jefferies BUY

SECTORS PEERS

PEERPRICE
MRNA$144.23COMPARE
RVMD$210.88COMPARE
RPRX$63.63COMPARE
ASND$271.19COMPARE
JAZZ$247.75COMPARE
BBIO$75.45COMPARE
SMMT$16.88COMPARE
IONS$57.88COMPARE